Clinical Trials
27 trialsNCT06694454 2026-05-27
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06772623 2026-05-27
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
Phase 1/2 Recruiting
NCT05789082 2026-05-18
KRAScendo 170
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05173142 2026-05-15
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT07579195 2026-05-14
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
University of Washington
Phase 1/2 Not yet recruiting
NCT05019716 2026-05-13
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT07397338 2026-05-12
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT06802835 2026-05-11
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT04083599 2026-05-06
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT07559929 2026-05-06
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06217757 2026-05-05
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Phase 1/2 Recruiting
NCT06996782 2026-05-01
ALTAIR
AstraZeneca
Phase 1/2 Recruiting
NCT01064648 2026-04-29
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT02535312 2026-04-17
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT06741644 2026-04-15
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT06624059 2026-04-08
HORIZON 2
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04938583 2026-04-06
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Active not recruiting
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT03473743 2026-03-30
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT07392541 2026-03-23
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Tongji Hospital
Phase 1/2 Recruiting
NCT03965234 2026-03-17
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT05410145 2026-03-12
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
D3 Bio (Wuxi) Co., Ltd
Phase 1/2 Recruiting
NCT07466160 2026-03-12
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT05229497 2026-03-09
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Akeso
Phase 1/2 Active not recruiting
NCT06162221 2026-03-09
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting